SHP 647

Drug Profile

SHP 647

Alternative Names: PF-00547659; PF-547659; SHP647

Latest Information Update: 05 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Pfizer
  • Class Antiulcers; Monoclonal antibodies
  • Mechanism of Action Alpha4-beta7 integrin antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ulcerative colitis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Crohn's disease; Ulcerative colitis

Most Recent Events

  • 30 Nov 2017 SHP 647 receives Orphan Drug status for Ulcerative colitis (In children) in USA
  • 28 Sep 2017 Shire plans the FIGARO UC 303 phase III trial for Ulcerative colitis (In children, In adolescents, In adults, maintenance therapy) (NCT03290781)
  • 19 Sep 2017 Shire plans the phase III AIDA trial for Ulcerative colitis in January 2018 (NCT03283085)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top